7,309 followers
RT @FDAOncology: FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma - via @CCR_AACR. 1st author Deepti Tel…
RT @FDAOncology: FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma - via @CCR_AACR. 1st author Deepti Tel…
RT @FDAOncology: FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma - via @CCR_AACR. 1st author Deepti Tel…
FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma - via @CCR_AACR. 1st author Deepti Telaraja, last author Nicole Gormley. https://t.co/1m1wY1ovIC #OCEPublications